| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | GP9; GPIX |
| Entrez GeneID | 2815 |
| clone | 4E2G7 |
| WB Predicted band size | 19kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD42A (AA: extra 17-147) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD42A抗体的3篇示例参考文献(内容为虚构示例，供参考格式)：
1. **《CD42A抗体在免疫性血小板减少症中的功能研究》**
- 作者：Smith J, et al.
- 摘要：本研究通过体外实验证明，CD42A抗体可通过阻断血小板糖蛋白GPIX与von Willebrand因子的相互作用，抑制血小板活化，为免疫性血小板减少症的机制提供了新见解。
2. **《新型抗CD42A单克隆抗体的开发及临床应用》**
- 作者：Li X, et al.
- 摘要：报道了一种高特异性CD42A单克隆抗体的制备方法，并验证其在流式细胞术中对血小板表面标志物的检测效能，提升了血栓性疾病的诊断灵敏度。
3. **《CD42A基因突变相关疾病的抗体靶向治疗探索》**
- 作者：Garcia R, et al.
- 摘要：针对CD42A突变引起的遗传性血小板功能障碍，研究团队利用人源化CD42A抗体在小鼠模型中成功恢复血小板聚集功能，为基因治疗提供了潜在策略。
4. **《CD42A抗体在抗血栓药物开发中的作用》**
- 作者：Wang Y, et al.
- 摘要：通过阻断CD42A与凝血因子的结合，该抗体显著减少动脉血栓形成，提示其作为新型抗血栓药物的开发价值。
(注：以上文献为示例，实际引用需检索PubMed、Web of Science等数据库获取真实研究。)
The CD42a antibody targets the glycoprotein IX (GPIX), a component of the platelet surface receptor complex GPIb-IX-V. This complex plays a critical role in primary hemostasis by mediating platelet adhesion to von Willebrand factor (VWF) at sites of vascular injury. CD42a (GPIX) associates with GPIbα (CD42b) and GPIbβ (CD42c) to form the functional receptor, which is essential for platelet activation and aggregation.
CD42a antibodies are widely used in diagnostic and research settings to identify and quantify platelets via flow cytometry, immunohistochemistry, or immunofluorescence. They are particularly valuable in diagnosing inherited platelet disorders, such as Bernard-Soulier syndrome (BSS), where mutations in GPIX or other complex components impair platelet function. In BSS, reduced or absent CD42a expression helps confirm the diagnosis.
Additionally, these antibodies aid in studying thrombocytopenia mechanisms, monitoring platelet transfusions, and evaluating megakaryocyte development in bone marrow. Their specificity makes them indispensable tools in hematology research and clinical laboratories for understanding platelet biology and related pathologies. Commercial CD42a clones (e.g., HI111) are validated for consistent performance across applications, ensuring reliability in both experimental and diagnostic workflows.
×
